Stock PDSB PDS BIOTECHNOLOGY CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases PDS Biotechnology Corporation

Equities

PDSB

US70465T1079

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-05 pm EDT 		5-day change 1st Jan Change
3.01 USD +3.79% Intraday chart for PDS Biotechnology Corporation +1.69% -39.44%
May. 15 PDS Biotechnology Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
May. 10 NetScientific says PDS Biotech's Versamune meets endpoints AN

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
PDS Biotechnology: Q1 Earnings Snapshot
AQ
PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results
AQ
PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer
AQ
PDS Biotech to Participate in Upcoming May 2024 Investor Conferences
AQ
PDS Biotech to Announce First Quarter 2024 Financial Results on May 15, 2024
AQ
PDS Biotechnology Announces Details of Virtual KOL Event
AQ
PDS Biotechnology Announces Details of Virtual KOL Event
AQ
PDS Biotech Appoints Stephan Toutain as Chief Operating Officer
AQ
PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune HPV in Combination with KEYTRUDA in Recurrent or Metastatic Head and Neck Cancer
AQ
PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer
AQ
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results
AQ
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results
AQ
PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results
AQ
PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®
AQ
PDS Biotechnology : Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune® - Form 8-K
PU
PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer
AQ
PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference
AQ
PDS Biotechnology Reports Inducement Grant under Nasdaq Listing Rule 5635(4)
AQ
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PDSB Stock
  4. News PDS Biotechnology Corporation
  5. Press Releases